Analysts’ Estimates and Ratings for Novartis in October


Dec. 4 2020, Updated 10:53 a.m. ET

Analysts’ revenue estimates

Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

Analysts expect the company’s EPS to be $1.31 on revenue of $13.0 billion in the third quarter, a ~5.0% rise compared to $12.4 billion in the third quarter of 2017.

The above chart compares the changes in analysts’ recommendations for Novartis since January.

Article continues below advertisement

Analysts’ recommendations

Analysts expect Novartis to return ~15.5% over the next 12 months. Analysts’ recommendations show a 12-month target price of $98.50 compared to its price of $85.26 on October 8.

Two analysts are tracking Novartis’s ADR (American depositary receipt). Both analysts have given it “strong buy” recommendations. No analysts have given it “holds” or “sells.”

Also, 26 analysts are tracking Novartis stock on the SIX Swiss Exchange. Of these, seven analysts have recommended “strong buys,” eight have recommended “buys,” and 11 have recommended “holds” on the stock. No analysts have recommended “sells.” The consensus rating for Novartis stock stands at 2.15, which represents a “strong buy” for long-term investors.

The Invesco BLDRS Developed Markets ADR ETF (ADRD) holds 5.4% of its total investments in Novartis, 2.5% in Sanofi (SNY), 2.5% in GlaxoSmithKline (GSK), and 2.5% in AstraZeneca (AZN).


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.